Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:C07K

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.20210317163Compositions And Methods For Simplified High Efficiency Isolation of Proteins
US 14.10.2021
Int.Class C07K 1/22
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
1General processes for the preparation of peptides
14Extraction; Separation; Purification
16by chromatography
22Affinity chromatography or related techniques based upon selective absorption processes
Appl.No 17225934 Applicant PLASMA TECHNOLOGIES, LLC Inventor Eugene Zurlo

Compositions and methods are provided that simplify isolation of proteins of interest from serum or plasma. Finely divided silica or a similar lipid/lipoprotein binding solid is used in combination with a protein precipitating agent to generate a solution that includes the protein of interest and that can be applied to chromatography media without resulting in significant fouling of the media. The method is particularly suitable for isolation of immunoglobulin G.

2.20210315838SYSTEMS, METHODS, AND KITS FOR DIAGNOSTICS AND TREATMENT OF VIRAL RESPIRATORY INFECTION
US 14.10.2021
Int.Class A61K 31/05
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
05Phenols
Appl.No 17301188 Applicant Applied Biology, Inc. Inventor Ofer A. Goren

The present disclosure includes methods, systems, kits and compositions for treating, preventing and diagnosing viral infections, specifically SARS-CoV-2 infections, with an anti-androgen and anti-thyroid medication, a thyroid receptor antagonist, a TGF-β inhibitor or a combination thereof. The present disclosure also describes methods and compositions for the treatment of viral respiratory diseases, specifically SARS-CoV-2 infections, including anti-androgens, anti-thyroid medications, thyroid receptor antagonists, TGF-β inhibitors, RXR inhibitors, furin inhibitors or other agents to disrupt the androgen signaling.

3.20210318334Materials and Methods for Improved Prediction of IGG Therapeutic Protein Exposure
US 14.10.2021
Int.Class G01N 33/68
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
68involving proteins, peptides or amino acids
Appl.No 17229124 Applicant Janssen Biotech, Inc. Inventor Yang Chen

Methods for predicting pharmacokinetics of an Immunoglobulin G (IgG) therapeutic protein based on a patient's level of rheumatoid factor (RF), anti-citrullinated protein antibodies (ACPA), or RF and ACPA. Methods disclosed herein also relate to methods for determining the therapeutically effective dose of an IgG therapeutic protein based on the levels of RF, ACPA, or RF and ACPA.

4.20210316003BIOMARKERS FOR SACITUZUMAB GOVITECAN THERAPY
US 14.10.2021
Int.Class A61K 47/68
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
68the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
Appl.No 17206388 Applicant Thomas M. Cardillo Inventor Thomas M. Cardillo

The present invention relates to biomarkers of use for treating Trop-2 expressing cancer with an anti-Trop-2 ADC comprising an anti-Trop-2 antibody conjugated to an inhibitor of topoisomerase I, preferably SN-38 or DxD. The anti-Trop-2 ADC may be administered as a monotherapy or as a combination therapy with one or more anti-cancer agents, such as DDR inhibitors. Therapy with the ADC alone or in combination with other anti-cancer agents can reduce solid tumors in size, reduce or eliminate metastases and is effective to treat cancers resistant to standard therapies. Preferably, the combination therapy has an additive effect on inhibiting tumor growth. Most preferably, the combination therapy has a synergistic effect on inhibiting tumor growth. In specific embodiments, the biomarker may relate to a gene selected from the group consisting of BRCA1, BRCA2, CHEK2, MSH2, MSH6, TP53, CDKN1A, BAG6, BRSK2, ERN1, FHIT, HIPK2, LGALS12, ZNF622, AEN, SART1, USP28, GADD45B, TGFB1, NDRG1, WEE1, PPP1R15A, MYBBP1A, SIRT1, ABL1, HRAS, ZNF385B, POLR2K and DDB2.

5.20210317170COMPOSITIONS AND METHODS FOR DRUG DELIVERY AND TREATING VIRAL INFECTIONS
US 14.10.2021
Int.Class C07K 14/165
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
08RNA viruses
165Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No 17086957 Applicant UT-Battelle, LLC Inventor Joseph Christopher Ellis

The present disclosure is directed to compositions and methods for targeted drug delivery that comprise a biocompatible framework carrying at least one drug and a viral surface protein, where the viral surface protein mediates entry into a target cell and is attached to an outer surface of the biocompatible framework in the drug carrier.

6.WO/2021/204714CAPILLARY GEL ELECTROPHORESIS AND ITS USE WITH COMPLEX BIOLOGICAL MOLECULES
WO 14.10.2021
Int.Class G01N 27/447
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
27Investigating or analysing materials by the use of electric, electro-chemical, or magnetic means
26by investigating electrochemical variables; by using electrolysis or electrophoresis
416Systems
447using electrophoresis
Appl.No PCT/EP2021/058775 Applicant ARES TRADING S.A. Inventor VASSALLO, Oscar
The invention described herein relates to an improved method for analytical capillary gel electrophoresis (CGE) for complex biologic molecules. The methods for the improved CGE include steps for the partial reduction of the biologic analyte molecule for use as calibration standard and use such partially reduced calibration sample to obtain an improved calibration curve for CGE to be used with biologic analyte molecules.
7.WO/2021/204878USE OF CDON INHIBITORS FOR THE TREATMENT OF ENDOTHELIAL DYSFUNCTION
WO 14.10.2021
Int.Class C07K 14/47
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
46from vertebrates
47from mammals
Appl.No PCT/EP2021/059066 Applicant INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) Inventor RENAULT, Marie-Ange
Endothelial dysfunction is a hallmark of peripheral arterial disease which is defined as vascular occlusion below the level of the inguinal ligament, and which is one of the most severe complications of diabetes and inflammatory conditions such as sepsis. Evidences accumulated within the past decades, identified Hedgehog (Hh) signaling as a new regulator of micro-vessel integrity. The purpose of the inventors was to investigate whether Hh co-receptors Gas1 and Cdon may be used as therapeutic targets to modulate Dhh signaling in ECs. The inventors demonstrated that both Gas1 and Cdon are expressed in adult ECs and relied on either siRNAs or EC specific conditional KO mice to investigate their role. They found that Gas1 deficiency mainly photocopies Dhh deficiency especially by inducing VCAM-1 and ICAM-1 overexpression while Cdon deficiency has opposite effects by promoting endothelial junction integrity. At a molecular level, Cdon prevents Dhh binding to Ptch1 and thus acts a decoy receptor for Dhh, while Gas1 promotes Dhh binding to Smo and as a result potentiates Dhh effects. Since Cdon is overexpressed in ECs treated by inflammatory cytokines including TNFα and Il1β, the inventors then tested whether Cdon inhibition would promote endothelium integrity in acute inflammatory conditions and found that both fibrinogen and IgG extravasation were decreased in association with an increased Cdh5 expression in the brain cortex of EC specific Cdon KO mice administered locally with Il1β. Altogether these results demonstrate that Cdon is a negative regulator and justify that Cdon blocking molecules may be used to promote endothelium integrity at least in inflammatory conditions.
8.WO/2021/204998NATURAL ANTIBODIES IN PROPHYLAXIS AND THERAPY
WO 14.10.2021
Int.Class A61K 39/04
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
02Bacterial antigens
04Mycobacterium, e.g. Mycobacterium tuberculosis
Appl.No PCT/EP2021/059294 Applicant HEIDELBERG IMMUNOTHERAPEUTICS GMBH Inventor ÜBELHART, Rudolf
Described is a human or humanized natural IgM and/or IgA antibody recognizing oxidized phospholipids and/or oxidation-specific epitopes for use in a method of treating or preventing a disorder or a disease associated with/related to/caused by a natural IgM/lgA antibody deficiency (NAD) in a subject. Moreover, described is a vaccine comprising a compound that induces the generation of natural IgM and/or IgA antibodies for use in a method of reducing or preventing the clinical signs or disease associated with/related to/caused by natural IgM/lgA antibody deficiency (NAD) in a subject, wherein said vaccine comprises a pharmaceutically acceptable carrier or excipient. Further, described is such a vaccine for use in a method of reducing or preventing the clinical signs or disease associated with/related to/caused by natural IgM/lgA antibody deficiency (NAD) in a subject, wherein said compound induces human natural IgM and/or IgA antibody recognizing oxidized phospholipids and/or oxidation-specific epitopes.
9.WO/2021/205208DEVICE FOR NORMALIZING HUMAN CELL GENE EXPRESSION AND WEAKENING CORONAVIRUS GENE EXPRESSION USING MAGNETIC AND ELECTROMAGNETIC FIELDS
WO 14.10.2021
Int.Class A61N 2/02
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
2Magnetotherapy
02using magnetic fields produced by coils, including single turn loops or electromagnets
Appl.No PCT/IB2020/053348 Applicant HASHEMI, Ali Inventor HASHEMI, Ali
The invention of device for normalizing human cell gene expression and weakening coronavirus gene expression using magnetic and electromagnetic fields which by making magnetic field and controlling the intensity, direction and wave length using servomotors, supports and electromagnetic wave generation module can make some changes in gene expression of viruses like corona to prevent from propagation and spread of virus. Also the magnetic field by making some natural changes in gene expression of human cells cause to indispose the environment for the propagation and growth of viruses and as a result cause the virus to be semi active. This magnetic field allows to treat the diseases with metabolic, bacterial, microbial and genetically origins.
10.WO/2021/205358COMPOSITIONS AND METHODS FOR BLOOD-BRAIN BARRIER DELIVERY
WO 14.10.2021
Int.Class A61K 47/68
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
68the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
Appl.No PCT/IB2021/052889 Applicant JANSSEN BIOTECH, INC. Inventor EDAVETTAL, Suzanne
Monoclonal anti-TfR antibodies and antigen-binding fragments thereof for delivering an agent to the brain of a subject in need thereof are described. Also described are conjugates and fusion constructs containing the anti-TfR antibody or antigen-binding fragment thereof coupled to a therapeutic or diagnostic agent, such as a second antibody and antigen-binding fragment thereof, for treating or detecting a neurological disorder and/or delivering a therapeutic or diagnostic agent across the blood-brain barrier. Also described are nucleic acids encoding the antibodies, conjugates and fusion constructs and related recombinant host cells.